REAGAN-UDALL FOUNDATION for the Food and Drug Administration

Addressing the Public Health Effects of Opioid Medications

September 9, 2026 | 12:30 – 4:30pm ET

Speaker Bios

Timothy J. Atkinson, PharmD
Acting Director, Opioid Safety, Specialty Care Program Office, U.S. Department of Veterans Affairs

Dr. Timothy Atkinson is the Acting Associate Director of Opioid Safety for the Office of Pain Management, Opioid Safety, PDMP (PMOP).

Dr. Atkinson previously served as the National Pain/Opioid Pharmacy Program Specialist for PMOP where he contributes to policy and guidance documents on opioid and pain related issues. Prior to working with PMOP, he served as a Clinical Pharmacy Practitioner, Pain Management and Director, PGY2 Pain Management & Palliative Care Pharmacy Residency Program at the VA Tennessee Valley Healthcare System. Dr. Atkinson represents pain on the VA Pharmacy Residency Advisory Board.

Robert Bailieu, MD, MPH
Physician & Senior Advisor, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration

Dr. Robert Baillieu serves as a physician and senior advisor at the Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT). In this role Dr. Baillieu has contributed to work on national policies related to the treatment of opioid use disorder and stimulant use disorder, while also contributing to multiple publications available in the SAMHSA Library. He is also involved in departmental evaluation efforts that seek to assess and promote best practices in treatment. Dr. Baillieu graduated with honors from the University of Sydney Medical School in Australia and completed residency training in family medicine at The University of Texas Health Science Center in San Antonio, where he was also chief resident. Prior to this, Dr. Baillieu lived in Australia where he undertook training in adult internal medicine. He is a board-certified family physician and a former Robert L. Phillips, Jr., Health Policy

Fellow at the American Academy of Family Physicians' Robert Graham Center and The U.S. Health Resources and Services Administration, Bureau of Primary Care. He holds degrees in medicine, health science, public health, business and modern languages, and has experience in health systems research, policy analysis, community organizing, international business, management, public health, education and medical practice. Dr. Baillieu is also a former assistant professor of clinical family medicine at Georgetown University where he supervised residents and taught classes in policy, advocacy, statistics and clinical medicine. Dr. Baillieu's research activities have focused on the primary care workforce, health IT and the implementation of best practices at the community level. He has presented at national and international meetings, as well as published in international, peer-reviewed journals.

Wilson M. Compton, MD, MPE
Deputy Director, National Institute on Drug Abuse

Dr. Wilson M. Compton is Deputy Director of the National Institute on Drug Abuse of the National Institutes of Health. Before joining NIDA in 2002, Dr. Compton was a tenured faculty member in the Department of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed residency training in psychiatry at Washington University in Saint Louis.

Over his career, Dr. Compton has achieved multiple scientific accomplishments. He has authored over 200 publications, including widely-cited papers on the U.S. opioid crisis., and has been an invited speaker at multiple high-impact venues. He was a member of DSM-5's Revision Task Force and has led, for NIDA, development of the Population Assessment of Tobacco and Health Study (PATH), a longitudinal population study, jointly sponsored by NIDA and the U.S. Food and Drug Administration (FDA), with 45,971 baseline participants who provide survey responses and biological assessments to inform the development of tobacco regulations in the United States.

Dr. Compton is a member of numerous professional organizations, including the Alpha Omega Alpha Medical Education Honor Society. Dr. Compton is also the recipient of multiple awards, including the Senior Scholar Health Services Research Award from the American Psychiatric Association in 2008 and the Paul Hoch Award from the American Psychopathological Association in 2010. The FDA selected him to receive collaboration and cross-cutting awards in 2012, 2013 and 2017. In 2018, Dr. Compton received the James W. West award from the National Association of Addiction Treatment Providers. Dr. Compton also received the Health and Human Services Secretary's Awards for Meritorious Service in 2013 and Distinguished Service in 2015, 2018 2019, and, most recently in 2024 for leadership of the CMS-NIH-CDC-SAMHSA Opioid Policy Data Team.

In 2024, he also received the American Public Health Association Rema Lapouse Award for significant contributions to integrating science in mental health epidemiology and public health.

Michael Davis, MD, PhD
Acting Director, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)

Dr. Michael Davis is the Deputy Center Director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). In this role, Dr. Davis serves on CDER's senior leadership team and supports the Center Director by providing executive leadership on strategic initiatives that advance CDER's mission to deliver safe, effective and high-quality medications.

Dr. Davis completed a Medical Scientist Training Program (MD, PhD in Pharmacology) at Case Western Reserve University, psychiatric residency training at the Semel Institute for Neuroscience and Human Behavior at UCLA, and a clinical research fellowship at the West Los Angeles VA Mental Illness Research, Education, and Clinical Center (MIRECC); his research interests focused on the development of novel therapeutics for schizophrenia. Following completion of his fellowship in 2014, he was a Staff Psychiatrist at the Michael E. DeBakey VA Medical Center in Houston, TX, and an Assistant Professor in the Baylor College of Medicine Department of Psychiatry and Behavioral Sciences. Dr. Davis is licensed to practice medicine and is board certified in Psychiatry.

From 2016–2022, Dr. Davis served in CDER's Office of New Drugs (OND) as a Clinical Team Leader in the Division of Psychiatry, where he led multidisciplinary teams in the review of drugs for the treatment of psychiatric disorders, as well as contributed to regulatory science and policy development. In this role, he received numerous honors and awards, including the Division of Psychiatry Annual Awards for Individual Supervisor and for Collaboration, and the FDA Outstanding Service Award for leadership in advancing science in psychiatric drug development. Dr. Davis also presented nationally and internationally on regulatory topics such as estimands, digital health technologies, and issues related to development of psychedelic-based therapies. After leaving the Agency in 2022, Dr. Davis served from 2022-2025 as Chief Medical Officer for a nonprofit medical research organization developing psychedelic drugs for the treatment of major depressive disorder and post-traumatic stress disorder. In 2025, Dr. Davis returned to the Agency in his current role.

Kristine Schmit, MD, MPH
Medical Officer, Health Systems and Research Branch, Division of Overdose Prevention, U.S. Centers for Disease Control and Prevention

Dr. Kristine Schmit is a medical officer in the Health Systems and Research Branch of CDC's Division of Overdose Prevention. Kristine attended medical school at Duke University and completed her Family Medicine residency at the University of California at San Diego. After finishing residency, she practiced for two and a half years at a Federally Qualified Health Center in Washington, DC before returning to North Carolina to complete her Preventive Medicine Residency at the University of North Carolina at Chapel Hill. Subsequently, she split her time practicing at a rural clinic in Henderson, North Carolina and conducting primary care research with the Duke Primary Care Research Consortium. Kristine completed an Epidemic Intelligence Service Fellowship at CDC with the Division of TB Elimination from 2015-2017 and then transitioned to a full-time position as a medical epidemiologist within the same Division where she served for nearly three years before transitioning to her current position with the Division of Overdose Prevention in 2021.

Marta Sokolowska, PhD
Deputy Center Director for Substance Use and Behavioral Health, CDER, FDA

Dr. Marta Sokolowska is the Deputy Center Director for Substance Use and Behavioral Health in FDA's Center for Drug Evaluation and Research (CDER). She serves as the center's executive-level leader responsible for advancing FDA's public health response to the non-medical use of substances with abuse potential. With expertise in science-based assessment and management of drug abuse risks, Dr. Sokolowska advises senior FDA officials on shaping scientific and policy interventions and executing strategies pertaining to the use of controlled substances and behavioral health programs.

Dr. Sokolowska joined CDER in 2018 as Associate Director for Controlled Substances in the Office of the Center Director. In 2020, she began leading the Controlled Substances Program (CSP), which comprises the Controlled Substance Staff (CSS) and the Controlled Substances Initiatives (CSI) group. CSS provides consultation throughout FDA on evaluation of abuse potential of drugs and advises on all matters related to domestic and international drug scheduling. The strategy group pursues activities and policies to identify, mitigate, and manage emerging issues with controlled substances to minimize risks associated with problematic use while enabling appropriate access to these products for medical use.

Dr. Sokolowska is a recognized expert in drug abuse liability and scheduling strategies. She has facilitated numerous initiatives to improve public health by advancing the science of assessing drug abuse liability. Prior to joining FDA, Dr. Sokolowska held senior clinical and medical leadership roles in the pharmaceutical industry. She earned her doctoral degree in psychology from McMaster University in Canada.

Moderator

Susan C. Winckler, RPh, Esq.
CEO, Reagan-Udall Foundation for the FDA

Susan C. Winckler, RPh, Esq., is CEO of the Reagan-Udall Foundation for the Food and Drug Administration. Prior to accepting the Foundation post, Ms. Winckler served as President of Leavitt Partners Solutions. As President and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advised corporate executives on policy and business matters. As CEO of the Food & Drug Law Institute, she provided attorneys, regulators, and other stakeholders with a neutral forum to address domestic and global issues. As Chief of Staff for the FDA (2007-2009), Winckler managed the Commissioner's Office, served both Republican and Democratic commissioners as their senior-most staff adviser, analyzed complex policy challenges, and represented FDA with myriad government entities and external stakeholders. Her earlier career service included more than a decade at the American Pharmacists Association. Winckler earned a bachelor's degree from the University of Iowa College of Pharmacy and her law degree magna cum laude from Georgetown University Law Center. She is an APhA Fellow, served as an elected member of the United States Pharmacopeial Convention (USP) Board of Trustees (2015-2020, 2020-2025) and Chair of that Board from 2019 to mid-2025. In 2023, she received the Distinguished Alumni Award of the Food and Drug Administration Alumni Association and, separately, was awarded the Osterhaus Medal for Lifetime Achievement by the Univ. of Iowa College of Pharmacy.